Discounted Cash Flow (DCF) Analysis Levered

TScan Therapeutics, Inc. (TCRX)

$2.82

+0.11 (+4.06%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
Operating Cash Flow --------
Operating Cash Flow (%)
Capital Expenditure --------
Capital Expenditure (%)
Free Cash Flow --------

Weighted Average Cost Of Capital

Share price $ 2.82
Beta 0.000
Diluted Shares Outstanding 11.66
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.878
Total Debt 6.04
Total Equity 32.89
Total Capital 38.93
Debt Weighting 15.52
Equity Weighting 84.48
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Operating Cash Flow --------
Capital Expenditure --------
Free Cash Flow --------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -155.36
Equity Value -
Shares Outstanding 11.66
Equity Value Per Share -